Vaccination with recombinant FimH fused with flagellin enhances cellular and humoral immunity against urinary tract infection in mice. (Q48041390)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23306365%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

title

Vaccination with recombinant FimH fused with flagellin enhances cellular and humoral immunity against urinary tract infection in mice (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23306365%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

main subject

urinary tract infection

1 reference

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23306365%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

Mehdi Mahdavi

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23306365%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

S Bouzari

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23306365%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

author name string

Mohammad Reza Asadi Karam

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23306365%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

Mehri Habibi

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23306365%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

language of work or name

English

0 references

publication date

7 January 2013

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23306365%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23306365%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

volume

31

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23306365%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

issue

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23306365%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

page(s)

1210-1216

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23306365%20AND%20SRC:MED&resulttype=core&format=json

TLR- and CXCR1-dependent innate immunity: insights into the genetics of urinary tract infections

22 February 2020

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.12.059

Role of Uropathogenic Escherichia coli Virulence Factors in Development of Urinary Tract Infection and Kidney Damage

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.12.059

Mechanisms and consequences of bladder cell invasion by uropathogenic Escherichia coli.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.12.059

In vivo gene expression analysis identifies genes required for enhanced colonization of the mouse urinary tract by uropathogenic Escherichia coli strain CFT073 dsdA.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.12.059

Role of motility in the colonization of uropathogenic Escherichia coli in the urinary tract

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.12.059

Host subversion by formation of intracellular bacterial communities in the urinary tract

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.12.059

Adhesion and entry of uropathogenic Escherichia coli.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.12.059

complex interplay between type 1 fimbrial expression and flagellum-mediated motility of uropathogenic Escherichia coli

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.12.059

Extensive mosaic structure revealed by the complete genome sequence of uropathogenic Escherichia coli.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.12.059

FdeC, a Novel Broadly Conserved Escherichia coli Adhesin Eliciting Protection against Urinary Tract Infections

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.12.059

Prevention of mucosal Escherichia coli infection by FimH-adhesin-based systemic vaccination

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.12.059

Uropathogenic Escherichia coli outer membrane antigens expressed during urinary tract infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.12.059

Vaccination utilizing the FimCH complex as a strategy to prevent Escherichia coli urinary tract infections

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.12.059

Type 1 pilus-mediated bacterial invasion of bladder epithelial cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.12.059

Development of intracellular bacterial communities of uropathogenic Escherichia coli depends on type 1 pili.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.12.059

Localization of a domain in the FimH adhesin of Escherichia coli type 1 fimbriae capable of receptor recognition and use of a domain-specific antibody to confer protection against experimental urinary tract infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.12.059

The Siderophore receptor IroN of extraintestinal pathogenic Escherichia coli is a potential vaccine candidate

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.12.059

A live-attenuated vaccine for the treatment of urinary tract infection by uropathogenic Escherichia coli

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.12.059

Vaccination with recombinant fusion proteins incorporating Toll-like receptor ligands induces rapid cellular and humoral immunity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.12.059

Flagellin is an effective adjuvant for immunization against lethal respiratory challenge with Yersinia pestis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.12.059

Flagellin fusion proteins as adjuvants or vaccines induce specific immune responses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.12.059

Effects of flagellin on innate and adaptive immunity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.12.059

Toll-like receptor 5 recognizes a conserved site on flagellin required for protofilament formation and bacterial motility

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.12.059

Salmonella flagellins are potent adjuvants for intranasally administered whole inactivated influenza vaccine.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.12.059

New malaria vaccine candidates based on the Plasmodium vivax Merozoite Surface Protein-1 and the TLR-5 agonist Salmonella Typhimurium FliC flagellin.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.12.059

Flagellin-F1-V fusion protein is an effective plague vaccine in mice and two species of nonhuman primates

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.12.059

A bacterial flagellin, Vibrio vulnificus FlaB, has a strong mucosal adjuvant activity to induce protective immunity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.12.059

Epitope-based vaccine against influenza

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.12.059

A West Nile virus recombinant protein vaccine that coactivates innate and adaptive immunity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.12.059

Single step protocol to purify recombinant proteins with low endotoxin contents.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.12.059

Epigenetic regulation of TLR4 gene expression in intestinal epithelial cells for the maintenance of intestinal homeostasis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.12.059

Flagellin acting via TLR5 is the major activator of key signaling pathways leading to NF-kappa B and proinflammatory gene program activation in intestinal epithelial cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.12.059

Cloning, expression, and immunogenicity of novel fusion protein of Mycobacterium tuberculosis based on ESAT-6 and truncated C-terminal fragment of HSP70.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.12.059

A multiepitope subunit vaccine conveys protection against extraintestinal pathogenic Escherichia coli in mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.12.059

Intranasal immunization with recombinant PspA fused with a flagellin enhances cross-protective immunity against Streptococcus pneumoniae infection in mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.12.059

Cellular mechanisms of the adjuvant activity of the flagellin component FljB of Salmonella enterica Serovar Typhimurium to potentiate mucosal and systemic responses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.12.059

Bacterial flagellin is an effective adjuvant for CD4+ T cells in vivo

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.12.059

Effectiveness of novel PGM-containing incomplete Seppic adjuvants in rabbits

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.12.059

Immunomodulatory activity of novel adjuvant formulations based on Montanide ISA oil-based adjuvants and peptidoglycan monomer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.12.059

Longevity of antibody and cytokine responses following vaccination with high potency emergency FMD vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.12.059

The innate immune response to uropathogenic Escherichia coli involves IL-17A in a murine model of urinary tract infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.12.059

Bacteria-induced uroplakin signaling mediates bladder response to infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.12.059

Susceptibility of immunodeficient gene-knockout mice to urinary tract infection.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.12.059